• Valentin Goede, Paula Cramer, Raymonde Busch, Manuela Bergmann, Martina Stauch, Georg Hopfinger, Stephan Stilgenbauer, Hartmut Döhner, Anne Westermann, Clemens M Wendtner, Barbara Eichhorst, Michael Hallek, and German CLL Study Group.
• Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany Department of Geriatric Medicine and Research, St. Marien Hospital and University of Cologne, Germany valentin.goede@uk-koeln.de.
• Haematologica. 2014 Jun 1; 99 (6): 1095-100.

AbstractThis study investigated the impact of comorbidity in 555 patients with chronic lymphocytic leukemia enrolled in two trials of the German Chronic Lymphocytic Leukemia Study Group on first-line treatment with fludarabine plus cyclophosphamide, fludarabine, or chlorambucil. Patients with two or more comorbidities and patients with less than two comorbidities differed in overall survival (71.7 versus 90.2 months; P<0.001) and progression-free survival (21.0 versus 31.5 months; P<0.01). After adjustment for other prognostic factors and treatment, comorbidity maintained its independent prognostic value in a multivariate Cox regression analysis. Chronic lymphocytic leukemia was the major cause of death in patients with two or more comorbidities. Disease control in patients with two or more comorbidities was better with fludarabine plus cyclophosphamide than with fludarabine treatment, but not with fludarabine compared to chlorambucil treatment. These results give insight into interactions between comorbidity and therapy of chronic lymphocytic leukemia and suggest that durable control of the hematologic disease is most critical to improve overall outcome of patients with increased comorbidity. The registration numbers of the trials reported are NCT00276848 and NCT00262795. Copyright© Ferrata Storti Foundation.

20 keywords...

hide…